Literature DB >> 32632072

[A Meta-Analysis on the Effects of Mind-Body Therapy on Patients with Irritable Bowel Syndrome].

Eun Hui Choi1, Moon Ja Kim2, Eun Nam Lee3.   

Abstract

PURPOSE: Previous randomized controlled trials (RCT) found that mind-body therapy can improve the health outcomes of patients with irritable bowel syndrome (IBS). The purpose of this meta-analysis was to identify the combined effects of mind-body therapy on patients' IBS symptoms, quality of life, anxiety, and depression.
METHODS: A systematic literature search was conducted using various databases such as PubMed, EMBASE, CINAHL CENTRAL, DBpia, RISS, and KISS. The primary outcome variables were IBS symptoms and quality of life; the secondary outcome variables were anxiety and depression. Comprehensive Meta-Analysis version 3.0 was used to analyze the extracted data. The effect size was calculated using standardized mean difference (SMD) and 95% confidence interval (CI).
RESULTS: Eleven final RCTs were used for this meta-analysis. Mind-body therapy was found to have a significant effect on the IBS patients' symptoms (SMD, -0.63; 95% CI, -0.77 to -0.48), quality of life (SMD, 1.03; 95% CI, 0.40 to 1.66), anxiety (SMD, -0.28; 95% CI, -0.47 to -0.09), and depression (SMD, -0.31; 95% CI, -0.06 to -0.12).
CONCLUSION: This meta-analysis reveals that mind-body therapy significantly improves IBS patients' symptoms, quality of life, anxiety, and depression. The results suggest that, in the future, appropriate mind-body therapy should be applied to Koreans suffering from IBS. Moreover, the therapy's long-term effects should be assessed.
© 2020 Korean Society of Nursing Science.

Entities:  

Keywords:  Irritable Bowel Syndrome; Meta-Analysis; Mind-Body Therapies; Quality of Life

Mesh:

Year:  2020        PMID: 32632072     DOI: 10.4040/jkan.19224

Source DB:  PubMed          Journal:  J Korean Acad Nurs        ISSN: 2005-3673            Impact factor:   0.984


  25 in total

Review 1.  Measuring inconsistency in meta-analyses.

Authors:  Julian P T Higgins; Simon G Thompson; Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2003-09-06

Review 2.  Irritable bowel syndrome: a model of the brain-gut interactions.

Authors:  Agata Mulak; Bruno Bonaz
Journal:  Med Sci Monit       Date:  2004-04

Review 3.  Psychosocial aspects of the functional gastrointestinal disorders.

Authors:  Rona L Levy; Kevin W Olden; Bruce D Naliboff; Laurence A Bradley; Carlos Francisconi; Douglas A Drossman; Francis Creed
Journal:  Gastroenterology       Date:  2006-04       Impact factor: 22.682

4.  Mind-body interventions: applications in neurology.

Authors:  Helané Wahbeh; Siegward-M Elsas; Barry S Oken
Journal:  Neurology       Date:  2008-06-10       Impact factor: 9.910

5.  Bias in meta-analysis detected by a simple, graphical test.

Authors:  M Egger; G Davey Smith; M Schneider; C Minder
Journal:  BMJ       Date:  1997-09-13

Review 6.  Systematic review of the comorbidity of irritable bowel syndrome with other disorders: what are the causes and implications?

Authors:  William E Whitehead; Olafur Palsson; Kenneth R Jones
Journal:  Gastroenterology       Date:  2002-04       Impact factor: 22.682

7.  The Differences in Prevalence and Sociodemographic Characteristics of Irritable Bowel Syndrome According to Rome II and Rome III.

Authors:  Dong Won Park; Oh Young Lee; Sung Gon Shim; Dae Won Jun; Kang Nyeong Lee; Hye Young Kim; Hang Lak Lee; Byung Chul Yoon; Ho Soon Choi
Journal:  J Neurogastroenterol Motil       Date:  2010-04-28       Impact factor: 4.924

Review 8.  Convergence of neuro-endocrine-immune pathways in the pathophysiology of irritable bowel syndrome.

Authors:  Maria M Buckley; Siobhain M O'Mahony; Dervla O'Malley
Journal:  World J Gastroenterol       Date:  2014-07-21       Impact factor: 5.742

Review 9.  [The pathophysiology of irritable bowel syndrome: inflammation and motor disorder].

Authors:  Hyojin Park
Journal:  Korean J Gastroenterol       Date:  2006-02

10.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.

Authors:  David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G Altman
Journal:  BMJ       Date:  2009-07-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.